Sequential Treatment of Bioresponsive Nanoparticles Elicits Antiangiogenesis and Apoptosis and Synergizes with a CD40 Agonist for Antitumor Immunity.
Sign Up to like & getrecommendations! Published in 2020 at "ACS nano"
DOI: 10.1021/acsnano.0c07132
Abstract: The combination of antiangiogenesis and chemotherapy regimens with cancer immunotherapy has the potential to synergistically boost antitumor immunity. Herein, we report the construction of two bioresponsive nanoparticles, namely, Podo-NP and CbP-NP, comprising prodrugs of podophyllotoxin… read more here.
Keywords: cd40 agonist; antitumor immunity; treatment; sequential treatment ... See more keywords
CD40 Agonist Antibodies in Cancer Immunotherapy.
Sign Up to like & getrecommendations! Published in 2019 at "Annual review of medicine"
DOI: 10.1146/annurev-med-062518-045435
Abstract: CD40 is a cell-surface member of the TNF (tumor necrosis factor) receptor superfamily. Upon activation, CD40 can license dendritic cells to promote antitumor T cell activation and re-educate macrophages to destroy tumor stroma. Numerous agonist… read more here.
Keywords: medicine; cd40 agonist; cd40; cancer ... See more keywords
Abstract 5079: Intratumoral CD40 agonist enhances the antitumor effect of anti-PD1 immunotherapy by activation of antigen-presenting cells and selective expansion of effector CD8+ T cells
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-5079
Abstract: Agonistic CD40 antibodies have shown promise when used in combination with checkpoint inhibitors in clinical trials for the treatment of malignancies. However, the mechanisms driving antitumor immune responses in patients are not well understood. The… read more here.
Keywords: anti pd1; combination; therapy; cd40 agonist ... See more keywords